Business Wire

'True Stories of Investing' - flatexDEGIRO drives financial education with high-quality documentation

28.1.2022 12:48:00 EET | Business Wire | Press release

Share

With "True Stories of Investing", flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing retail online broker collaborates with award-winning documentary maker, New Amsterdam, and Discovery, to demystify investing. The documentary premieres on Discovery's channels across Europe starting this weekend and showcases important lessons every retail investor needs to know. In four episodes, renowned journalists, professors, behavioral scientists and investors challenge some of the biggest misconceptions about investing by examining historical events and the mechanisms at work.

Frank Niehage, CEO of flatexDEGIRO: "It is our mission to retailise capital markets and empower private individuals to invest in a self-determined and sustainable way. As Europe's leading online broker, we feel responsible for making trading more simple, more informed, and more secure for our customers. With this innovative documentary, we take financial education one step further. We are very proud to be the first online broker to collaborate with New Amsterdam and Discovery on this important topic and to be part of this outstanding and informative production.

" Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "In 2021, we have optimised our pricing structure, including commission-free trading of stocks and ETFs in different markets, significantly extended our product offering and invested heavily into IT to provide the highest stability and security on our platforms. Together with a strong push for educational marketing, this unmatched combination of best-in class platforms, products and prices should encourage 250 million people in Europe to invest appropriately and sustainably."

Award-winning director Lyangelo Vasquez delves into the world of investing. The documentary explains the difference between active and passive investing, an exploration that starts with the friendly bet Warren Buffett made against an active fund manager, ultimately proving that a long-term, 'boring' investment strategy can be just as successful.

The documentary also shows how to diversify risk over sectors, regions, and time, while impact investors Mark van Baal and former F1 World Champion, Nico Rosberg, outline how investing can in fact contribute to a better world.

In the course of the documentary, behavioural scientists and pioneers like Hersh Shefrin (Professor at Santa Clara University and best-selling author of "Beyond Greed and Fear") and Wendy De La Rosa (TED speaker and PhD Stanford University) explain how investing requires mental discipline to not get caught in your own brain's psychology of FOMO (Fear Of Missing Out), cognitive bias, confirmation bias and extrapolation bias. These can lead to mechanisms driving markets away from fundamental values as well as creating bubbles and crashes as witnessed by BBC Journalist Rory Cellan-Jones.

About flatexDEGIRO AG

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution at top TIER 1 exchanges. Its technological edge as well as high levels of efficiency and strong economies of scale allows flatexDEGIRO to continuously improve its value proposition to clients, including commission-free brokerage.

With more than 2 million customer accounts and over 90 million securities transactions settled in 2021, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customer accounts, settling 250-350 million transactions per year - even in years with low volatility.

More information via https://www.flatexdegiro.com/en

Additional features:

Picture: https://eqs-cockpit.com/c/fncls.ssp?u=a07f12c4555ef094194edefc9bbf46ae

Subtitle: We challenge the biggest misconceptions about investing

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information please contact:
Achim Schreck
Head of IR & Corporate Communications
flatexDEGIRO AG
Rotfeder-Ring 7
D-60327 Frankfurt/Main
Tel. +49 (0) 69 450001 0
achim.schreck@flatexdegiro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye